CS
GNMX

Credit Suisse’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Credit Suisse’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,578
Closed -$71K – 4194
2016
Q4 		$71K Buy
13,578
+3,461
+34% +$18.2K ﹤0.01% 3992
2016
Q3 		$56K Sell
10,117
-2,245
-18% -$12.8K ﹤0.01% 4007
2016
Q2 		$69K Buy
+12,362
New +$64.9K ﹤0.01% 4117
2015
Q2 		– Sell
-38,992
Closed -$314K – 4696
2015
Q1 		$314K Buy
+38,992
New +$294K ﹤0.01% 3839

Other funds holding GNMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse's GNMX Position: Q1 2017 in Review

Credit Suisse sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2017, closing a stake of 13,578 shares — an estimated $71K sold.

Credit Suisse first reported a position in GNMX in Q1 2015 and held it in 4 quarters. The position peaked at $314K in Q1 2015. 73 funds tracked by Wall St. Rank hold GNMX as of Q1 2017.

  • Credit Suisse reported no remaining Aevi Genomic Medicine Inc position as of Q1 2017 after selling out during the quarter.
  • Credit Suisse sold 13,578 Aevi Genomic Medicine Inc shares in Q1 2017, an estimated $71K.
  • Credit Suisse first reported a position in Aevi Genomic Medicine Inc in Q1 2015 and held it in 4 quarters.
  • Credit Suisse's Aevi Genomic Medicine Inc position peaked at $314K in Q1 2015.
  • 73 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2017.

Based on Credit Suisse's 13F filing for Q1 2017, filed 15 May 2017.